Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US (RIM)

NCT07301008 Phase 4 RECRUITING

Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.

Details

Lead sponsor	Medstar Health Research Institute
Phase	Phase 4
Status	RECRUITING
Enrolment	60
Start date	2025-09-09
Completion	2027-01

Conditions

• Migraine
• Trigger Induced Migraine

Interventions

• Rimegepant 75 MG

Primary outcomes

• Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity — 24 hour post dose
  Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity occurs within 24 hours

Countries

United States